Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05553366 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
A Phase 3 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,075
- Enrollment target
NCT05553366: Completed Phase 3 study, sponsored by Vertex Pharmaceuticals Incorporated.
NCT05553366 is a Phase 3 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 1,075 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05553366, a Phase 3 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,075 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of suzetrigine for acute pain after a bunionectomy.
Primary Outcome
SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated subtracting the baseline pain intensity score from the pain intensity score at each postdose time point (using pain rating score range: 0= no pain to 10= worst possible pain). SPID48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).
Interventions
- DRUG Placebo (matched to SUZ)
- DRUG HB/APAP
- DRUG Placebo (matched to HB/APAP)
- DRUG SUZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,075 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 3 |
What the finished NCT05553366 record still lists
NCT05553366 is an interventional study that assigns participants to a tested intervention. Its 1,075 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo (matched to SUZ) is the first listed.
NCT05553366 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05553366 about?
NCT05553366 is a clinical study titled "Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy". The purpose of this study is to evaluate the efficacy and safety of suzetrigine for acute pain after a bunionectomy.
What is the current status of trial NCT05553366?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,075 participants. The study started on 2022-10-03. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT05553366?
The interventions under investigation include: Placebo (matched to SUZ) (DRUG), HB/APAP (DRUG), Placebo (matched to HB/APAP) (DRUG), SUZ (DRUG).
Who is sponsoring clinical trial NCT05553366?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05553366's enrollment target sits among peer trials
1,075 271st of 2000 higher than 1,730 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
- NCT07084883 · 1,076 participants
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
- NCT06159673 · 1,074 participants · Phase 2
ACP-204 in Adults With Alzheimer's Disease Psychosis
- NCT06751043 · 1,072 participants · NA
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI